Frankfurt - Delayed Quote EUR

BioCryst Pharmaceuticals, Inc. (BO1.F)

8.39

-0.49

(-5.47%)

As of 1:08:53 PM GMT+1. Market Open.

BioCryst Launches ORLADEYO® (berotralstat) in Portugal

RESEARCH TRIANGLE PARK, N.C., Feb. 12, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that Infarmed in Portugal has recommended ORLADEYO® (berotralstat) for the routine prevention of recurrent attacks of hereditary angioedema (HAE) in eligible patients 12 years and older. With this recommendation, HAE patients in Portugal will have access to the first oral, once-daily therapy for the reduction of recurrent HAE attacks. “The positive Infarmed recommendation

GlobeNewswire yesterday

BCRX
Exploring Three High Growth Tech Stocks In The United States

In the last week, the United States market has been flat, yet it has seen a 20% increase over the past year with earnings projected to grow by 15% annually. In this context of robust growth potential, identifying high-growth tech stocks that align with these promising market conditions can be crucial for investors seeking opportunities in this dynamic sector.

Simply Wall St. 3 days ago

BCRX

WDAY

ROKU
BioCryst to Present New ORLADEYO® (berotralstat) Results from APeX-P Pediatric Trial at 2025 American Academy of Allergy, Asthma & Immunology / World Allergy Organization Joint Congress

RESEARCH TRIANGLE PARK, N.C., Feb. 10, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present five abstracts featuring new clinical and real-world outcomes with oral, once-daily ORLADEYO® (berotralstat) for the prophylactic treatment of hereditary angioedema (HAE) at the 2025 American Academy of Allergy, Asthma & Immunology (AAAAI) / World Allergy Organization (WAO) joint congress. Included among these is a late-breaking abstract that

GlobeNewswire 3 days ago

BCRX
BioCryst to Report Fourth Quarter 2024 Financial Results on February 24

RESEARCH TRIANGLE PARK, N.C., Feb. 10, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its fourth quarter 2024 financial results on Monday, February 24, 2025. BioCryst management will host a conference call and webcast at 8:30 a.m. ET that day to discuss the financial results and provide a corporate update. The live call may be accessed by dialing 1-844-481-2942 for domestic callers and 1-412-317-1866 for international callers.

GlobeNewswire 3 days ago

BCRX
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

RESEARCH TRIANGLE PARK, N.C., Feb. 04, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted eight newly-hired employees stock options to purchase an aggregate of 22,575 shares, and restricted stock units (RSUs) covering an aggregate of 27,550 shares, of BioCryst common stock. The options and RSUs were granted as of January 31, 2025, as inducements material to each employee entering into emp

GlobeNewswire 9 days ago

BCRX
Bullish BioCryst Pharmaceuticals Insiders Loaded Up On US$1.05m Of Stock

Generally, when a single insider buys stock, it is usually not a big deal. However, when several insiders are buying...

Simply Wall St. 13 days ago

BCRX
BioCryst price target raised to $12 from $10 at Evercore ISI

Evercore ISI raised the firm’s price target on BioCryst (BCRX) to $12 from $10 and keeps an Outperform rating on the shares. The company preannounced 2024 Orladeyo revenue of $437M, $2M ahead of the upper end of the guidance range and beating consensus by $4M, notes the analyst, who thinks 2025 guidance of $515-$535M for Orladeyo revenue is “conservative” when considering the 5% price increase and availability of funds to cover Medicare copay this year. Published first on TheFly – the ultimate s

TipRanks 30 days ago

BCRX
Exploring High Growth Tech Stocks In January 2025

The United States market has remained flat over the past week but has shown a robust 23% increase over the past year, with earnings projected to grow by 15% annually. In this environment, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation and adaptability to capitalize on these favorable conditions.

Simply Wall St. last month

ARBE

ARBEW

DV
BioCryst Announces Preliminary Full Year 2024 ORLADEYO® (berotralstat) Net Revenue of $437 Million (+34 percent y-o-y)

—ORLADEYO net revenue expected to be between $515-$535 million in 2025— —Total revenue (including RAPIVAB®) expected to be between $540-$560 million in 2025— —Company achieved operating profit in 2024 (not including stock-based compensation) and expects to approach quarterly EPS profitability/positive cash flow in 2H 2025— —New drug application planned in 2025 for ORLADEYO granules in children up to age 12; will address significant unmet need— —Pipeline advancing into patients with Netherton syn

GlobeNewswire last month

BCRX
BioCryst to Present at 43rd Annual J.P. Morgan Healthcare Conference

RESEARCH TRIANGLE PARK, N.C., Jan. 07, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 14, 2025, at 6:00 p.m. ET. Link to the live audio webcast and replay of the presentation may be accessed in the Investors & Media section of BioCryst’s website at www.biocryst.com. About BioCryst PharmaceuticalsBioCryst Pharmaceuticals is a global biotec

GlobeNewswire last month

BCRX
The 4.5% return this week takes BioCryst Pharmaceuticals' (NASDAQ:BCRX) shareholders five-year gains to 127%

When you buy shares in a company, it's worth keeping in mind the possibility that it could fail, and you could lose...

Simply Wall St. last month

BCRX
High Growth Tech Stocks To Watch In December 2024

Over the last 7 days, the U.S. market has risen 1.1%, and over the past 12 months, it is up by an impressive 32%, with earnings forecasted to grow by 16% annually. In this environment of robust growth, identifying high-growth tech stocks involves looking for companies that are well-positioned to capitalize on technological advancements and expanding market opportunities.

Simply Wall St. 2 months ago

BCRX

YOU

ARQT
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Is Expected To Breakeven In The Near Future

BioCryst Pharmaceuticals, Inc. ( NASDAQ:BCRX ) is possibly approaching a major achievement in its business, so we would...

Simply Wall St. 2 months ago

BCRX
BioCryst Launches ORLADEYO® (berotralstat) in Ireland

RESEARCH TRIANGLE PARK, N.C., Nov. 18, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Health Services Executive (HSE) in Ireland has recommended ORLADEYO® (berotralstat) for the routine prevention of recurrent attacks of hereditary angioedema (HAE) in eligible patients 12 years and older. With this recommendation, HAE patients in Ireland will have access to the first oral, once-daily therapy for the reduction of recurrent HAE attacks. “The positiv

GlobeNewswire 2 months ago

BCRX
BioCryst to Present at Upcoming Investor Conferences

RESEARCH TRIANGLE PARK, N.C., Nov. 06, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company plans to present at the following conferences: 2024 Jefferies London Healthcare Conference on Wednesday, November 20, 2024, at 5:00 a.m. ET.7th Annual Evercore HealthCONx Conference in Coral Gables on Wednesday, December 4, 2024, at 2:35 p.m. ET.Piper Sandler 36th Annual Healthcare Conference in New York on Thursday, December 5, 2024, at 8:30 a.m. ET. Lin

GlobeNewswire 3 months ago

BCRX
BioCryst Announces Strong Q3 2024 Revenue Growth

BioCryst ( (BCRX) ) has issued an announcement. BioCryst Pharmaceuticals reported a strong Q3 2024 with ORLADEYO net revenue of $116.3 million, growing 35.7% year-over-year, and adjusted full-year revenue guidance to $430-$435 million. The company introduced additional revenue guidance of $443-$448 million including RAPIVAB and achieved a GAAP operating profit of $7.7 million. Advancements in their pipeline include BCX17725 for Netherton syndrome and avoralstat for DME, showcasing significant pr

TipRanks 3 months ago

BCRX
BioCryst Pharmaceuticals Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

BioCryst Pharmaceuticals ( NASDAQ:BCRX ) Third Quarter 2024 Results Key Financial Results Revenue: US$117.1m (up 35...

Simply Wall St. 3 months ago

BCRX
Q3 2024 BioCryst Pharmaceuticals Inc Earnings Call

Q3 2024 BioCryst Pharmaceuticals Inc Earnings Call

Thomson Reuters StreetEvents 3 months ago

BCRX
BioCryst Pharmaceuticals Inc (BCRX) Q3 2024 Earnings Call Highlights: Strong ORLADEYO Growth ...

BioCryst Pharmaceuticals Inc (BCRX) reports robust revenue growth and strategic progress, while navigating market challenges and future opportunities.

GuruFocus.com 3 months ago

BCRX
BioCryst Pharmaceuticals (BCRX) Q3 2024 Earnings Call Transcript

BCRX earnings call for the period ending September 30, 2024.

Motley Fool 3 months ago

BCRX

Performance Overview

Return	BO1.F	S&P 500
YTD	+14.70%	+3.11%
1-Year	+52.95%	+22.44%
3-Year	-47.29%	+37.25%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

BioCryst Pharmaceuticals, Inc. (BO1.F)

BioCryst Launches ORLADEYO® (berotralstat) in Portugal

Exploring Three High Growth Tech Stocks In The United States

BioCryst to Present New ORLADEYO® (berotralstat) Results from APeX-P Pediatric Trial at 2025 American Academy of Allergy, Asthma & Immunology / World Allergy Organization Joint Congress

BioCryst to Report Fourth Quarter 2024 Financial Results on February 24

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Bullish BioCryst Pharmaceuticals Insiders Loaded Up On US$1.05m Of Stock

BioCryst price target raised to $12 from $10 at Evercore ISI

Exploring High Growth Tech Stocks In January 2025

BioCryst Announces Preliminary Full Year 2024 ORLADEYO® (berotralstat) Net Revenue of $437 Million (+34 percent y-o-y)

BioCryst to Present at 43rd Annual J.P. Morgan Healthcare Conference

The 4.5% return this week takes BioCryst Pharmaceuticals' (NASDAQ:BCRX) shareholders five-year gains to 127%

High Growth Tech Stocks To Watch In December 2024

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Is Expected To Breakeven In The Near Future

BioCryst Launches ORLADEYO® (berotralstat) in Ireland

BioCryst to Present at Upcoming Investor Conferences

BioCryst Announces Strong Q3 2024 Revenue Growth

BioCryst Pharmaceuticals Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

Q3 2024 BioCryst Pharmaceuticals Inc Earnings Call

BioCryst Pharmaceuticals Inc (BCRX) Q3 2024 Earnings Call Highlights: Strong ORLADEYO Growth ...

BioCryst Pharmaceuticals (BCRX) Q3 2024 Earnings Call Transcript

Performance Overview